Shelter Pharma Ltd (543963)

Shelter Pharma's Board approved the conversion of 4,65,000 warrants into 4,65,000 equity shares of ₹10 face value to promoter Mustaqim Nisarahmed Sabugar. The company received the remaining 75% exercise price of ₹31.6875 per share, totaling ₹1.47 crore against an issue price of ₹42.25 per warrant. Following this allotment, the paid-up equity share capital increased from ₹16.84 crore to ₹17.30 crore. The promoter's outstanding balance of convertible warrants is now nil.

• 4,65,000 warrants converted into equity shares of face value ₹10 each
• Raised ₹14,734,687.50 upon receipt of balance 75% exercise price (₹31.6875 per share)
• Issue price per warrant fixed at ₹42.25 (including a premium of ₹32.25)
• Paid-up share capital increased from ₹16,83,67,920 to ₹17,30,17,920 (1,73,01,792 equity shares)
• Promoter Mustaqim Nisarahmed Sabugar has 0 balance warrants remaining from his initial 7,50,000 allocation

Shelter Pharma's Board approved the conversion of 4,65,000 warrants into 4,65,000 equity shares of ₹10 face value to promoter Mustaqim Nisarahmed Sabugar. The company received the remaining 75% exercise price of ₹31.6875 per share, totaling ₹1.47 crore against an issue price of ₹42.25 per warrant. Following this allotment, the paid-up equity share capital increased from ₹16.84 crore to ₹17.30 crore. The promoter's outstanding balance of convertible warrants is now nil.

• 4,65,000 warrants converted into equity shares of face value ₹10 each
• Raised ₹14,734,687.50 upon receipt of balance 75% exercise price (₹31.6875 per share)
• Issue price per warrant fixed at ₹42.25 (including a premium of ₹32.25)
• Paid-up share capital increased from ₹16,83,67,920 to ₹17,30,17,920 (1,73,01,792 equity shares)
• Promoter Mustaqim Nisarahmed Sabugar has 0 balance warrants remaining from his initial 7,50,000 allocation

Shelter Pharma reported receiving positive feedback on social media from Dr. C.M. Patel regarding its human healthcare products. The review covered products including Lemonade Barley Water, Alkaliser syrup, and Joemega capsules. The filing was made voluntarily under Regulation 30, and the company explicitly stated it expects no immediate material impact on its financials. Against Shelter Pharma's TTM revenue of ₹124 Cr and market cap of ₹42 Cr, the development is purely promotional and non-quantifiable.

• Feedback received from Dr. C.M. Patel on social media covering Lemonade Barley Water, Alkaliser syrup, and Joemega capsules
• Company explicitly reported zero expected immediate material financial impact from the event
• Voluntary disclosure under Regulation 30 concerning brand credibility in the Human Healthcare segment

Shelter Pharma Limited has received an international purchase order from Berlin International Company for nutraceutical supplies valued at USD 10,150 (approx. Rs 9.72 Lakhs). The order entails the supply of 3,500 units of D3 CURE 50 ML at USD 2.90 per unit. Given the company's TTM revenue of Rs 124 Cr, the order represents less than 0.01% of annual sales and is financially immaterial. The engagement represents a small step in diversifying export revenues, though execution timelines remain subject to purchase order schedules.

• Order size is USD 10,150 or Rs 9,72,360.86
• Scope covers 3,500 units of D3 CURE 50 ML at USD 2.90 per unit
• Awarded by overseas client Berlin International Company in the normal course of business
• Execution timeline set within mutually agreed schedules as per purchase order

Shelter Pharma Ltd has announced the launch of an in-house developed herbal healthcare product, SHELTIDIN DS (Cough Spray), effective August 20, 2026. The throat-soothing spray caters initially to the domestic Indian market and is available on e-commerce platforms. The company generated TTM revenue of ₹124 Cr and net profit of ₹16 Cr, but has not disclosed expected sales contributions or capex figures for this launch.

• Launched SHELTIDIN DS – Cough Spray in the Herbal Human Healthcare segment on August 20, 2026
• Product is available domestically across reputed e-commerce platforms
• Developed in-house by the company's R&D team at FDA-GMP approved facilities
• Targeted initially at the domestic market, with plans to explore international opportunities in due course

Shelter Pharma Limited has completed manufacturing and fully dispatched an export order worth USD 12,285 (approx. ₹0.10 crore) to Genet International, Bangladesh. The order comprised veterinary feed supplements including Feedmin Bolus, Regulin Bolus, Lactocal Gel, and Buta-B Bolus. The company confirmed that the order value has been fully settled with zero pending balance for dispatch. Given the company's TTM revenue of ₹124 crore, the financial impact of this transaction is immaterial.

• Completed and dispatched export order valued at USD 12,285 to Bangladesh
• Products supplied include Feedmin Bolus, Regulin Bolus, Lactocal Gel, and Buta-B Bolus
• Payment has been fully settled and balance pending dispatch is NIL
• Order size represents less than 0.1% of Shelter Pharma's TTM revenue of ₹124 crore

Shelter Pharma has successfully completed and dispatched an export order for 'All Vitamins Tablets' to Taha Drugs & Chemicals Co. Ltd in Sudan. The order is valued at USD 103,538 (approximately ₹0.87 Cr), which has been fully settled by the customer. While the order is a positive step for international expansion, it represents a minor fraction (approx. 0.7%) of the company's TTM revenue of ₹124 Cr. The company currently trades at a low P/E of 2.0 with a market capitalization of ₹33 Cr.

• Successfully dispatched export order worth USD 103,538 to Sudan.
• Order value represents approximately 0.7% of the TTM revenue of ₹124 Cr.
• Payment for the order has been fully settled by the customer, Taha Drugs & Chemicals Co. Ltd.
• Company maintains a low debt-to-equity ratio of 0.01 with a net worth of ₹77 Cr.

Shelter Pharma has appointed Dr. Vinita Shivraj Gadhvi as an Additional Independent Director for a five-year term effective July 31, 2026. Dr. Gadhvi brings over 12 years of experience in pharmaceuticals, healthcare innovation, and regulatory compliance, holding a Ph.D. in the Indian Healthcare Startup Ecosystem. This appointment to the board of the Rs 34 Cr market cap company is subject to shareholder approval. The company currently maintains a TTM revenue of Rs 124 Cr with an operating margin of 18.4%.

• Appointment of Dr. Vinita Shivraj Gadhvi for a fixed tenure of 5 consecutive years starting July 31, 2026.
• Dr. Gadhvi possesses over 12 years of experience across pharmaceuticals, healthcare innovation, and strategic growth.
• Academic credentials include a Ph.D. in Healthcare Startup Ecosystem and a Gold Medal in M.Pharm (Quality Assurance).
• The appointee has no reported relationships with existing Directors or Key Managerial Personnel.

Shelter Pharma has appointed Dr. Vinita Shivraj Gadhvi as an Additional Independent Director for a five-year term effective July 31, 2026. Dr. Gadhvi brings over 12 years of experience in pharmaceuticals, healthcare innovation, and quality systems, which aligns with the company's core business. Following this appointment, the company also reconstituted its Corporate Social Responsibility (CSR) Committee to include her as a member. This governance update comes as the company maintains a low P/E of 2.1 and a market capitalization of ₹34 Cr.

• Appointment of Dr. Vinita Shivraj Gadhvi for a fixed tenure of 5 consecutive years starting July 31, 2026.
• New director brings over 12 years of professional experience in pharmaceuticals and healthcare innovation.
• Board meeting conducted efficiently within 30 minutes, from 10:45 A.M. to 11:15 A.M.
• CSR Committee reconstituted with 4 members, including the Managing Director and two Independent Directors.

Shelter Pharma Ltd has received international purchase orders from Genet International for its veterinary feed supplement products. The total order value is USD 12,285 (approximately ₹10.2 lakhs), which is less than 0.1% of the company's TTM revenue of ₹124 Cr. The order includes products such as Feedmin Bolus, Regulin Bolus, Lactocal Gel, and Buta-B Bolus. While the company views this as a milestone for its international presence, the financial impact is negligible relative to its current scale.

• Total order value of USD 12,285 received from international entity Genet International
• Order includes 2,000 boxes of Feedmin Bolus and 2,500 boxes of Regulin Bolus
• Order value represents approximately 0.08% of the company's TTM revenue of ₹124 Cr
• Execution to be completed within mutually agreed timelines as per the purchase order schedule

Shelter Pharma Ltd has secured a small purchase order from Verka Dairy Ludhiana for the supply of veterinary feed supplements. The total order value is Rs 50,347.50, which is negligible (less than 0.01%) compared to the company's TTM revenue of Rs 124 Cr. The order involves the supply of DIA-VET BLOUS and UTRON products. While the financial impact is immaterial, the order establishes a business relationship with Verka, a prominent dairy brand under MILKFED Punjab.

• Total order value is INR 50,347.50 for veterinary feed supplements
• Order includes 1,000 units of DIA-VET BLOUS priced at Rs 17.20 per unit
• Order includes 600 units of UTRON priced at Rs 51.25 per unit
• The client, Verka Dairy Ludhiana, is a flagship brand of MILKFED Punjab
• Order is to be executed within mutually agreed timelines as per the purchase order